Home

 

COMPETE.
Phase III Clinical Trial.

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

EndolucinBeta®

ITM’s subsidiary ITG Isotope Technologies Garching GmbH recently received Marketing Authorization for EndolucinBeta / (n.c.a.) Lutetium (177Lu) chloride…

View details >>

April 18, 2017

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

Full releases >>

August 04, 2016

ITM´s subsidiary ITG receives Drug Approval for EndolucinBeta®

Full releases >>

May 10, 2016

EMA/CHMP adopts positive opinion for ITM’s EndolucinBeta®

Full releases >>

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>